Alercell names Jim Stipcich vice president of business development

Alercell has hired Montana executive Jim Stipcich to lead business development and strategic partnerships as the company prepares a planned pilot program in Montana. The appointment is aimed at helping the blood-cancer detection company secure clinical site agreements and research collaborations across the state and region.

Why it matters: - Alercell is building the partnership network it will need to test its planned Montana pilot program. - The role centers on clinical sites, laboratory relationships and research ties that could shape how the company evaluates its blood-cancer detection technology.

What happened: - Alercell appointed James “Jim” A. Stipcich as vice president of business development and strategic partnerships. - Stipcich had already been advising Alercell since July 2026. - The appointment was announced Oct. 27, 2026, from Bozeman, Montana. - Stipcich will lead partnership development across Montana and the surrounding region. - His work includes helping establish clinical site agreements for Alercell’s planned Montana pilot program. - He will also pursue collaborations with laboratories and research partners.

The details: - Stipcich brings 35 years of executive experience. - He previously led the Montana Higher Education Student Assistance Corporation and the Student Assistance Foundation of Montana. - In a 2017 presentation to the Montana Board of Regents, MHESAC reported that it had provided capital for student loans to more than 200,000 Montanans. - Stipcich also leads JASMT Business Consulting, LLC, a Helena-based firm that advises Montana businesses. - Alercell is a Bozeman-based company founded in June 2020. - Alercell is developing the LENA platform, which combines DNA methylation analysis with artificial intelligence to investigate earlier detection and risk assessment of blood cancers. - Alercell says presymptomatic detection remains a research goal. - The company says the early-detection work described in the release is research use only. - More information is available in Alercell's announcement.

Between the lines: - The hire suggests Alercell is moving from technology development toward the relationship-building phase needed to run a pilot. - Stipcich’s Montana network and experience in state leadership may help the company navigate local partnerships faster. - The focus on research use only and forward-looking language underscores that Alercell is still in an early validation stage.

What's next: - Stipcich is expected to help Alercell secure the clinical and research partnerships needed to move the pilot forward. - Alercell says the planned Montana pilot program and related product development remain subject to risks and uncertainties. - The company says actual results may differ materially from forward-looking statements. - Alercell says it has no obligation to update those statements except as required by law.